SCHEMBL5654750

SCHEMBL5654750

CC(N)c1cccc(N2CCOCC2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.50
CYP1A2 P05177 2/20 0.50
AGXT P21549 1/20 0.50
LMNA P02545 1/20 0.50
KCNQ3 O43525 1/20 0.50
KCNQ2 O43526 1/20 0.50
CYP19A1 P11511 1/20 0.50
CYP2C9 P11712 1/20 0.50
KMO O15229 1/20 0.49
CYP2D6 P10635 1/20 0.46
SLC6A2 P23975 1/20 0.46
SLC6A4 P31645 1/20 0.46
SLC6A3 Q01959 1/20 0.46
LGMN Q99538 1/20 0.45
PSEN1 P49768 1/20 0.44
PSEN2 P49810 1/20 0.44
APH1B Q8WW43 1/20 0.44
NCSTN Q92542 1/20 0.44
APH1A Q96BI3 1/20 0.44
PSENEN Q9NZ42 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8050667 1.00 CYP3A4 (0.50) CYP3A4CYP1A2AGXTLMNAKCNQ3
Hydrochloric Acid SCHEMBL6689154 0.98 CYP3A4 (0.49) CYP3A4CYP1A2AGXTLMNAKCNQ3
Hydrochloric Acid SCHEMBL3975530 0.98 CYP3A4 (0.49) CYP3A4CYP1A2AGXTLMNAKCNQ3
Hydrochloric Acid SCHEMBL6851464 0.98 CYP3A4 (0.49) CYP3A4CYP1A2AGXTLMNAKCNQ3
SCHEMBL276758 0.87 LMNA (0.53) CYP3A4CYP1A2AGXTLMNAKCNQ3
SCHEMBL296073 0.85 CYP3A4 (0.49) CYP3A4CYP1A2AGXTLMNAKCNQ3
SCHEMBL27475842 0.84 CYP3A4 (0.50) CYP3A4CYP1A2AGXTLMNAKCNQ3
SCHEMBL6647444 0.83 AGXT (0.50) CYP3A4CYP1A2AGXTLMNAKCNQ3
Hydrochloric Acid SCHEMBL5673046 0.83 CYP3A4 (0.52) CYP3A4CYP1A2AGXTLMNAKCNQ3
SCHEMBL783346 0.82 ADRA2C (0.62) AGXTALDH1A1MAPTHTTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2702043-A1 INHIBITORS OF INDUCIBLE FORM OF 6-PHOSPHOFRUCTOSE-2-KINASE Exelixis, Inc. (US) 2014-03-05 EP disclosed
WO-2012149528-A1 INHIBITORS OF INDUCIBLE FORM OF 6-PHOSPHOFRUCTOSE-2-KINASE EXELIXIS, INC. (US) 2012-11-01 WO disclosed
US-7091202-B2 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators BRISTOL-MYERS SQUIBB COMPANY (US) 2006-08-15 US disclosed
US-20060063790-A1 4-Arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators BRISTOL-MYERS SQUIBB COMPANY 2006-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063790-A1 4-Arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators KCNQ2, KCNQ1, KCNQ4 CYP3A4 380/4885CYP1A2 854/4885AGXT 3398/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.